CEO Corner

My Journey From "Science Guy" To CEO

I am a big believer in refining one's personal brand and even reinventing yourself to create opportunities for personal growth. During my career, some key truths and learnings have emerged that I feel privileged to share, and I hope these will be insightful and helpful.

Driving And Sustaining Innovation In Biopharma Today

We’ve arrived at a critical window for innovation in rare disease that must be treated with the same caliber and urgency that we saw nearly three years ago at the onset of the COVID-19 pandemic.

What I Learned As CEO The First Time Around

Less than 10% of novel compounds that enter Phase 1 clinical trials obtain FDA approval, which is why we followed a detailed roadmap for budgeting and advancing our new therapy at each stage of development.

The Model Of A Well-Funded Biotech Startup

Here are some business management changes to secure the future of biotech startups in 2023 and beyond.

Our Long Journey To FDA Approval

The financial markets, though, weren’t the cause of one of the most difficult periods I faced as CEO of AVEO Oncology. Instead, it was the decade-long journey we took to gain approval of our flagship kidney cancer drug, FOTIVDA (tivozanib), after significant regulatory and organizational setbacks.

How Diversity And Motherhood Fortified Me As A Women’s Health CEO

The lessons I have learned through my diverse background and motherhood are additive to those shared by many females who have stood up to share their perspectives and offer advice about how to break the pervasive glass ceiling.

Peeling Back The Layers Of The Digital Health Onion

Digital health has radically changed patient care globally and disrupted healthcare, whilst also increasing speed and efficiency through new healthcare models.

5 Mistakes To Avoid When Scaling Your Biotech Startup

My experiences have given me a deep well of expertise about the many factors that drive (or hinder) success as startups scale. Here are five traps founders must not fall victim to.

Why Russia’s Invasion Of Ukraine Threatens Our Vibrant Life Science Ecosystem

I posit that only pluralistic democracies committed to the rule of law can support the kind of investment and innovation our industry requires to thrive, while autocracies can’t make the same claim.

Recognizing The Value Of Biotech Partnerships In China

China’s pharmaceutical market operates under regulations that are closely aligned with world standards, and the companies making innovative in-roads into the market are fueled by regional and international biotech finance.